Technology

Reimagining 
in vivo cell therapy

CPTx is pioneering immune-silent single-stranded DNA (ssDNA) vectors as a new foundation for in vivo CAR T therapies. Our ssDNA + LNP platform is redosable, tunable, and durable, a clear contrast to viral & nonviral vectors that permanently integrate and to mRNA approaches that fade too quickly for oncology.

Our lead dual CAR program targets CD19/CD20 to treat relapsed/refractory diffuse large B-cell lymphoma, and we see broad potential for our in vivo CAR T platform to extend to additional hematologic malignancies, solid tumors, and—beyond oncology—autoimmune diseases.

Contact Us

Non-viral, durable, redosable.

Traditional viral delivery methods and mRNA face well-known limitations, including the risk of immune activation, restrictions on payload size, lack of tissue specificity, and significant manufacturing complexity. Our in vivo CAR-T therapies avoid these limitations.

Built with ssDNA + non viral LNPs, our in vivo CAR-T therapies offer:

Immune-silent, 
repeatable dosing

Precise tissue and 
cell targeting

Scalable, modular manufacturing

Tunable and 
durable effect

Beyond CAR-T

A versatile
platform

While we are currently focused on oncology, our platform can be leveraged for a variety of in vivo gene therapies, offering modular control over:

  • Payload mRNA & DNA for gene expression
  • Targeting ligands & receptor effectors
  • Combinatorial payloads for immune modulation

Built for a growing network of partners

We manufacture long, high-sequence-fidelity ssDNA constructs at research and clinical scale, serving CPTx and a growing network of partners.

Vector design and ssDNA manufacturing that set us apart

Pharmaceutical and biotech companies come to us not only for product innovation — but also for our unique ability to build what others can’t. We welcome collaborations across research, clinical development, and advanced DNA manufacturing.

Let’s build the future of CAR-T together.

We invite you to explore how our precision DNA therapies can accelerate your breakthroughs.

Explore Partnerships